Skip to main content

New and Emerging Prophylactic Agents for Migraine

CNS Drugs volume 16, pages 611–634 (2002)Cite this article

Abstract

Frequent, severe and long-lasting migraine attacks require prophylaxis. Established drugs used for the prevention of migraine such as β-adrenoceptor antagonists (β-blockers), calcium channel antagonists, antidepressants and others have an unknown mode of action in migraine. Their prophylactic effect in migraine was discovered by chance in clinical practice when these drugs were used for other purposes. Recently, research into the mechanisms of migraine and the progressive recognition that cortical hyperexcitability and an imbalance between neuronal inhibition [mediated by γ-aminobutyric acid (GABA)] and excitation (mediated by excitatory amino acids) may play an important role in migraine pathophysiology have lead to the identification of potential new agents for the prevention of migraine attacks. This paper reviews the recent literature on these new agents.

A search was conducted using MEDLINE from 1998 to November 2001 with the following search terms: migraine, preventive, prophylactic and treatment. Headache textbooks edited in 2000 and 2001 were also used.

After analysing the available controlled and uncontrolled clinical studies as well as abstracts, divalproex sodium (valproate semisodium) can be recommended for the prevention of migraine. Lamotrigine may be useful for preventing aura associated with migraine, and topiramate seems a promising option pending trials with more patients, which are currently underway. Riboflavin (which is possibly involved in improving neuronal energy production) appears to be a promising agent, although comparisons with established prophylactic medications are needed. Gabapentin, magnesium, lisinopril and botulinum toxin A have recently been suggested to be effective; however, at present, there are insufficient rigorous and reliable controlled data on these drugs for them to be indicated for such use. Emerging options such as tiagabine, levetiracetam, zonisamide and petasites may all be useful, but controlled data are required to confirm their efficacy. The anti-asthma medication montelukast was found to be effective in an open trial, but ineffective in a recently completed controlled trial.

There is an expectation that modern neuroscience will soon provide more efficacious and better tolerated prophylactic medications for migraine.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III
Table IV
Table V
Table VI

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Neurology 1994; 44Suppl. 14: S24–39

    PubMed  CAS  Google Scholar 

  2. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15: 45–68

    PubMed  CAS  Google Scholar 

  3. Steward WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 1996; 16: 231–8

    Article  Google Scholar 

  4. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8Suppl. 7: 1–96

    Google Scholar 

  5. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia 1997; 17: 67–72

    PubMed  CAS  Article  Google Scholar 

  6. Goadsby PJ, Edvinson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–7

    PubMed  CAS  Article  Google Scholar 

  7. Olesen J, Friberg L, Olsen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990; 28: 791–8

    PubMed  CAS  Article  Google Scholar 

  8. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligoemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981; 9: 344–52

    PubMed  CAS  Article  Google Scholar 

  9. Saxena PR. Cranial arteriovenous shunting: an in vivo animal model for migraine. In: Olesen J, Moskowitz MA, editors. Experimental headache models. Philadelphia (PA): Lippincott-Raven, 1995: 181–96

    Google Scholar 

  10. Mathew NT, Silberstein SD. Anticonvulsants in migraine prophylaxis. In: Diener HC, editor. Drug treatment of migraine and other headaches. Basel: Karger, 2000: 288–98

    Chapter  Google Scholar 

  11. Olesen J. Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications. Cerebrovasc Brain Metab Rev 1991; 3: 1–28

    PubMed  CAS  Google Scholar 

  12. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658–60

    PubMed  CAS  Article  Google Scholar 

  13. Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 385–9

    Google Scholar 

  14. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s headache and other head pain. 7th ed. New York: Oxford University Press, 2001: 121–246

    Google Scholar 

  15. Lance JW. Migraine prophylaxis: indication for drug therapy. In: Diener H-C, editor. Drug treatment of migraine and other headaches. Basel: Karger, 2000: 250–5

    Chapter  Google Scholar 

  16. Mathew NT, Silberstein SD. Anticonvulsants in migraine prophylaxis. In: Diener HC, editor. Drug treatment of migraine and other headaches. Basel: Karger, 2000: 288–98

    Chapter  Google Scholar 

  17. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine. 2nd ed. Cephalalgia 2000; 20: 765–86

    PubMed  CAS  Article  Google Scholar 

  18. Ramadan MN, Silberstein SD, Freitag FG, et al. Pharmacological management for prevention of migraine [online]. Available from URL: http://www.aan.com/public/practiceguidelines/05.pdf [Accessed 2001 Dec 20]

  19. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache, an evidence-based review. Neurology 2000; 55: 754–63

    PubMed  CAS  Article  Google Scholar 

  20. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988; 78: 346–8

    PubMed  CAS  Article  Google Scholar 

  21. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001; 15(6): 405–17

    PubMed  CAS  Article  Google Scholar 

  22. Hosford DA. Models of primary generalized epilepsy. Curr Opin Neurol 1995; 8(2): 121–5

    PubMed  CAS  Article  Google Scholar 

  23. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281–6

    PubMed  CAS  Article  Google Scholar 

  24. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study: Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 1999; 39: 633–43

    PubMed  CAS  Article  Google Scholar 

  25. Cutrer FM, Limmroth V, Ayata G, et al. Valproate reduces C-Fos expression in trigeminal nucleus caudalis (TNC) after noxious meningeal stimulation [abstract]. Cephalalgia 1995; 15Suppl. 14: 96

    Google Scholar 

  26. Cutrer FM, Moskowitz M. Actions of valproate and neuro-steroids in a model of trigeminal pain. Headache 1996; 36: 579–85

    PubMed  CAS  Article  Google Scholar 

  27. Viswanathan KN, Sundraram N, Rajendran C, et al. Sodium valproate in therapy of intractable headache with EEG changes. Cephalalgia 1991; 11: 282–3

    Google Scholar 

  28. Moore KL. Valproate in the treatment of refractory recurrent headaches: a retrospective analysis of 207 patients. Headache Q 1992; 3: 323–5

    Google Scholar 

  29. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12:81–4

    PubMed  CAS  Article  Google Scholar 

  30. Jensen R, Brink T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44: 647–51

    PubMed  CAS  Article  Google Scholar 

  31. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study: the Divalproex Sodium in Migraine Prophylaxis Study Group. Cephalalgia 1997; 17: 103–8

    PubMed  CAS  Article  Google Scholar 

  32. Kaniecki RG. A comparative study of propranolol and divalproex sodium in the prophylaxis of migraine. Arch Neurol 1997; 54: 1141–4

    PubMed  CAS  Article  Google Scholar 

  33. Pelloch JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving anti-epileptic drugs. Neurology 1991; 41: 961–4

    Article  Google Scholar 

  34. Driefuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379–85

    Article  Google Scholar 

  35. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22: 62–5

    PubMed  CAS  Article  Google Scholar 

  36. Vainionpaa LK, Rattya J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45: 444–50

    PubMed  CAS  Article  Google Scholar 

  37. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996; 36: 547–55

    PubMed  CAS  Article  Google Scholar 

  38. R&D Insight [database]. Auckland: Adis International, 2002

  39. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152–76

    PubMed  CAS  Article  Google Scholar 

  40. Lamb RJ, Leach MJ, Miller AA, et al. Anticonvulsant profile in mice of lamotrigine, a novel anticonvulsant [abstract]. Br J Pharmacol 1985; 85(4): 235

    Google Scholar 

  41. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II: neuro-chemical studies on the mechanism of action. Epilepsia 1986; 27: 490–7

    PubMed  CAS  Article  Google Scholar 

  42. Scheller D, Heister U, Dengler K, et al. Extracellular changes of aspartate and glutamate during generation and during propagation of cortical spreading depression in rats. In: Olesen J, editor. Migraine and other headaches: the vascular mechanisms. New York: Raven Press, 1991: 161–5

    Google Scholar 

  43. D’Andrea G, Granella F. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study [abstract]. Cephalalgia 1997; 17: 438

    Google Scholar 

  44. Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine vs placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109–12

    PubMed  CAS  Article  Google Scholar 

  45. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119–28

    PubMed  CAS  Article  Google Scholar 

  46. Edwards KR, Glantz MJ, Shea P, et al. Topiramate for migraine prophylaxis: a double-blind, randomized, placebo-controlled study [abstract]. Headache 2000; 40: 407

    Google Scholar 

  47. Potter DL, Hart DE, Calder CS, et al. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine [abstract]. Neurology 2000; 54Suppl. 3: A15

    Google Scholar 

  48. Lampl C, Buzath A, Klinger D, et al. Lamotrigine in the prophylactic treatment of migraine aura: a pilot study. Cephalalgia 1999; 19:58–63

    PubMed  CAS  Article  Google Scholar 

  49. D’Andrea G, Granella F, Cadaldini M, et al. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19: 64–6

    PubMed  Article  Google Scholar 

  50. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 39Suppl. 7: 22–6

    Article  Google Scholar 

  51. Shachter SC. Epilepsy. Neurol Clin 2001; 19: 57–78

    Article  Google Scholar 

  52. Gram L. Pharmacokinetics of new antiepileptic drugs. Epilepsia 1996; 37Suppl. 6: S12–6

    PubMed  CAS  Article  Google Scholar 

  53. Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995; 18: 469–81

    PubMed  CAS  Article  Google Scholar 

  54. Kelly KM. Gabapentin: antiepileptic mechanism of action. Neuropsychobiology 1998; 38(3): 139–44

    PubMed  CAS  Article  Google Scholar 

  55. Tremont-Lukats IW, Megef C, Backonja M-M. The anticonvulsants in neuropathic painful syndromes. Drugs 2000; 60(5): 1029–52

    PubMed  CAS  Article  Google Scholar 

  56. Caraceni A, Zecca E, Martini C, et al. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 1999; 17: 441–5

    PubMed  CAS  Article  Google Scholar 

  57. Khan O. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51: 611–4

    PubMed  CAS  Article  Google Scholar 

  58. Mathew NT. Gabapentin in migraine prophylaxis [abstract]. Cephalalgia 1996; 16: 367

    Article  Google Scholar 

  59. Morris GL. Efficacy and tolerability of gabapentin in clinical practice. Clin Ther 1995; 17: 891–900

    PubMed  Article  Google Scholar 

  60. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000; 41: 35–9

    Article  Google Scholar 

  61. Gibbs JW, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: blockade of kainite-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41: S10–6

    PubMed  CAS  Article  Google Scholar 

  62. Sigel E. Functional modulation of ligand-gated GABAA and NMDA receptor channels by phosphorylation. J Recept Signal Transduct Res 1995; 15: 325–32

    PubMed  CAS  Article  Google Scholar 

  63. Doose DR, Walker SA, Gisclon LG, et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996; 36: 884–91

    PubMed  CAS  Google Scholar 

  64. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 41Suppl. 1:61–5

    Article  Google Scholar 

  65. Shuaib A, Ahmed F, Muratoglu M, et al. Topiramate in migraine prophylaxis: a pilot study [abstract]. Cephalalgia 1999; 19: 379–80

    Google Scholar 

  66. Krusz JC, Scott V. Topiramate in the treatment of chronic migraine and other headaches [abstract]. Headache 1999; 39: 363

    Google Scholar 

  67. Edwards KR, Kamin M. The beneficial effect of slowing the initial titration rate of topiramate [abstract]. Neurology 1997; 48: A39

    Article  Google Scholar 

  68. Jones MW. Topiramate — safety and tolerability. Can J Neurol Sci 1998; 25: 13–5

    Google Scholar 

  69. Gubbay SS. Letters to the editor [letter]. Epilepsia 1998; 39: 451

    PubMed  CAS  Article  Google Scholar 

  70. Banta JT, Hoffman K, Budenz DL, et al. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001; 132: 112–4

    PubMed  CAS  Article  Google Scholar 

  71. Reife RA, Lim P, Pledger P. Topiramate: side effect profile in double-blind studies [abstract]. Epilepsia 1995; 36Suppl. 4: 34

    Google Scholar 

  72. Reife RA. Topiramate a novel anti-epileptic agent. In: Shorvon S, Dreifuss F, Fish D, et al., editors. The treatment of epilepsy. London: Blackwell Science, 1996: 471–81

    Google Scholar 

  73. Rhee DJ, Goldberg MJ, Parrish RK. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol 2001; 119: 1721–3

    PubMed  CAS  Google Scholar 

  74. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994; 14: 328–9

    PubMed  CAS  Article  Google Scholar 

  75. Welch KMA, Levine SR, Dándrea G, et al. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorous 31 NMR spectroscopy. Neurology 1989; 39: 538–41

    PubMed  CAS  Article  Google Scholar 

  76. Hershey AD, Powers SW, Bentti A-L, et al. Chronic daily headaches (CDH) in children characteristics and treatment response [abstract]. Headache 1999; 39: 358

    Google Scholar 

  77. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 1998; 50: 466–70

    PubMed  CAS  Article  Google Scholar 

  78. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257–63

    PubMed  CAS  Article  Google Scholar 

  79. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine: a double-blind, placebo-controlled study. Cephalalgia 1996; 16: 436–40

    PubMed  CAS  Article  Google Scholar 

  80. Silberstein SD, Mathew NT, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment [abstract]. The BOTOX® Migraine Clinical Research Group. Headache 2000; 40: 445–50

    PubMed  CAS  Article  Google Scholar 

  81. Pfaffenrath V, Schoenen J, Tfelt-Hansen P. Migraine prophylaxis: other drugs. In: Diener H-C, editor. Drug treatment of migraine and other headaches. Basel: Karger, 2000: 299–306

    Chapter  Google Scholar 

  82. Swanson DR. Migraine and magnesium: eleven neglected connections. Perspect Biol Med 1988; 31: 526–7

    PubMed  CAS  Google Scholar 

  83. Ramadan NM, Halvorson H, Vande-Linde A, et al. Low brain magnesium in migraine. Headache 1989; 29: 590–3

    PubMed  CAS  Article  Google Scholar 

  84. Welch KMA, D’Andrea G, Tepley N, et al. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1990; 8: 807–28

    Google Scholar 

  85. Pines N, Kieff MB, Lond LMSSA. Magnesium sulphate in the treatment of angiospasm. Lancet 1933; I: 577–9

    Article  Google Scholar 

  86. Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31: 298–301

    PubMed  CAS  Article  Google Scholar 

  87. Binder WJ, Brin MF, Blitzer A, et al. Botulin toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000; 123: 669–76

    PubMed  CAS  Article  Google Scholar 

  88. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981; 33: 155–88

    PubMed  CAS  Google Scholar 

  89. Volknandt W. Commentary: the synaptic vesicle and its targets. Neuroscience 1995; 64: 277–300

    PubMed  CAS  Article  Google Scholar 

  90. Binder W, Brin MF, Blitzer A, et al. Botulinum toxin type A (BTX-A) for migraine: an open label assessment [abstract]. Mov Disord 1998; 13Suppl. 2: 241 (P4-104)

    Google Scholar 

  91. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995; 36: 612–26

    PubMed  CAS  Article  Google Scholar 

  92. Adkins JC, Noble S. Tiagabine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55(3): 437–60

    PubMed  CAS  Article  Google Scholar 

  93. DrakeJr ME, Kay AM, Knapp MS, et al. An open-label trial of tiagabine for migraine prophylaxis [abstract]. Headache 1999; 39: 352

    Google Scholar 

  94. Freitag FG, Diamond S, Diamond ML, et al. The prophylaxis of migraine with the GABA-agonist, tiagabine: a clinical report [abstract]. Headache 1999; 39: 354

    Google Scholar 

  95. Parantainen J, Vapaatalo H, Hokkanen E. Clinical aspects of prostaglandins and leukotrienes (LT) in migraine. Cephalalgia 1986; 6Suppl. 4:95–101

    PubMed  Google Scholar 

  96. Zhao JJ, Rogers JD, Holland SD, et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 2000; 18(9): 769–77

    Article  Google Scholar 

  97. Sheftell F, Rapoport A, Weeks R, et al. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 2000; 40: 158–63

    PubMed  CAS  Article  Google Scholar 

  98. Singulair® (montelukast sodium): tablets and chewable tablets [package insert]. Whitehouse Station (NJ): Merck & Company, 2001 Feb

  99. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss Syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117: 708–13

    PubMed  CAS  Article  Google Scholar 

  100. Stoloff S, Stempel DA. Churg-Strauss Syndrome: is there an association with leukotriene modifiers? Chest 2001; 118: 1515–6

    Article  Google Scholar 

  101. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent model of seizures and epilepsy [abstract]. Eur J Pharmacol 1998; 353: 191

    PubMed  CAS  Article  Google Scholar 

  102. Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999; 27: 250–4

    PubMed  CAS  Google Scholar 

  103. Krusz JC. Levetiracetam as prophylaxis for resistant headaches [abstract]. Cephalalgia 2001; 21: 373

    Google Scholar 

  104. Drake ME, Greathouse NI, Armentbright AD, et al. Levetiracetam for preventive treatment of migraine [abstract]. Cephalalgia 2001; 21: 373

    Google Scholar 

  105. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20(6): 593–7

    PubMed  CAS  Article  Google Scholar 

  106. Ito T, Hori M, Kadokawa T. Effects of zonisamide (AD-810) on tungstic acid gel-induce thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharge in cats. Epilepsia 1986; 27: 367–74

    PubMed  CAS  Article  Google Scholar 

  107. Drake ME, Greathouse NI, Armentbright AD, et al. Preventive treatment of migraine with zonisamide [abstract]. Cephalalgia 2001; 21: 374

    Google Scholar 

  108. Krusz JC. Zonisamide in the treatment of headache disorders [abstract]. Cephalalgia 2001; 21: 374–5

    Google Scholar 

  109. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies: our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 79–85

    PubMed  CAS  Article  Google Scholar 

  110. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67–73

    PubMed  CAS  Article  Google Scholar 

  111. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin converting enzyme. Clin Exp Hypertens A 1987; 9: 243–59

    PubMed  CAS  Article  Google Scholar 

  112. Belllissant E, Nguyen PC, Giudicelli JF. Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. J Cardiovasc Pharmacol 1996; 28: 470–8

    Article  Google Scholar 

  113. Langtry HD, Markham A. Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 1997; 10: 131–66

    PubMed  CAS  Article  Google Scholar 

  114. Saenz-Campos D, Bayes MC, Masana E, et al. Sex-related pharmacokinetic and pharmacodynamic variations of lisinopril. Methods Find Exp Clin Pharmacol 1996; 18: 533–8

    PubMed  CAS  Google Scholar 

  115. Paterna S, DiPasquale P, D’Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000; 43: 133–6

    PubMed  CAS  Article  Google Scholar 

  116. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. BMJ 2001; 322: 19–22

    PubMed  CAS  Article  Google Scholar 

  117. Ware JE, Gandek B, IQOLA project group. The SF-36 heath survey:development and use in mental health research and the IQOLA project. Int J Ment Health 1994; 23: 49–73

    Google Scholar 

  118. Eaton J. Butterbur, herbal help for migraine. Natural Pharmacother 1998; 2: 23–4

    Google Scholar 

  119. Mauskop A. Petasites hybridus: ancient medicinal plant is effective prophylactic treatment for migraine. Townsend Lett 2000; 38: 430–5

    Google Scholar 

  120. Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000; 38: 430–5

    PubMed  CAS  Google Scholar 

  121. Lipton RB, Gobel H, Wilks K, et al. Efficacy of petasites (an extract from petasites rhizome) 50 and 75 mg for prophylaxis of migraine: results of a randomized, double-blind, placebo controlled study [abstract]. Neurology 2002; 58: A472

    Article  Google Scholar 

  122. Lin H, Chien CH, Lin YL, et al. Inhibition of testosterone secretion by S-petasin in rat testicular interstitial cells. Chin J Physiol 2000; 43: 99–103

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This review did not receive any financial support or help. Although the authors have presented lectures to various pharmaceutical companies, they are not engaged or have any source of interest with any company whatsoever.

Author information

Affiliations

  1. Department of Neurology, Universidade Federal Fluminense and Institute of Neurology Deolindo Couto, Av das Americas 1155/1608, Barra, Rio de Janeiro, Brazil, 22631.000

    Abouch V. Krymchantowski

  2. Military Police of Rio, Rio de Janeiro, Brazil

    Abouch V. Krymchantowski

  3. The New England Center for Headache, Stamford, Connecticut, USA

    Marcelo E. Bigal

  4. Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA

    Marcelo E. Bigal

  5. Department of Neurology, Universidade Federal Fluminense, Rio de Janeiro, Brazil

    Pedro F. Moreira

Authors
  1. Abouch V. Krymchantowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcelo E. Bigal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pedro F. Moreira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abouch V. Krymchantowski.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Krymchantowski, A.V., Bigal, M.E. & Moreira, P.F. New and Emerging Prophylactic Agents for Migraine. Mol Diag Ther 16, 611–634 (2002). https://doi.org/10.2165/00023210-200216090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200216090-00003

Keywords

  • Migraine
  • Valproate
  • Botulinum Toxin
  • Gabapentin
  • Lamotrigine